HCV Core Protein Protein (AA 2-192) (beta-Gal)

N° du produit ABIN621534

Détail du produit

Antigène: HCV Core Protein (HCV C) (Hepatitis C Virus Core Protein (HCV C))

Type de proteíne: Recombinant

Attributs du protein: AA 2-192

Origine: Hepatitis C Virus (HCV)

Hôte: Veuillez nous consulter SVP

Purification/Conjugué: Cette HCV Core Protein protéine est marqué à la beta-Gal.

Application: Western Blotting (WB), ELISA

Séquence: mstnpkpqrk tkrntnrrpq dvkfpgvgqi vggvyllprr gprlgvratr ktsersqprg rrqpipkarr pegrtwaqpg ypwplygneg cgwagwllsp rgsrpswgpt dprrrsrnlg kvidtltcgf adlmgyiplv gaplggaara lahgvrvled gvnyatgnlp gcsfsiflla llscltvpa.

Specificité: Immunoreactive with sera of HCV-infected individuals.

Attributs du produit: Recombinant Hepatitis C Virus Nucleocapsid (core) 22 kDa

Purification: HCV-Core protein was purified by proprietary chromatographic technique.

Pureté: > 95 % pure as determined by 10 % PAGE (coomassie staining).

Information d'application

Indications d'application: HCV-Core Antigen is suitable for ELISA and Western blots, excellent antigen for detection of HCV with minimal specificity problems.

Restrictions: For Research Use only

Stockage

Buffer: 20mM Tris Hcl pH-8, 8M urea and 10mM beta-mercaptoethanol.

Stock: -20 °C

Détail du antigène

Antigène: HCV Core Protein (HCV C) (Hepatitis C Virus Core Protein (HCV C))

Abstract: HCV C Produits

Classe de substances: Viral Protein

Sujet: The E. coli derived recombinant protein contains the HCV core nucleocapsid genotype 1b, immunodominant regions, AA 2-192, 22 kDa. The protein is fused with b-galactosidase (114 kDa) at N-terminus. Introduction: HCV is a small 50nm, enveloped, single-stranded, positive sense RNAvirus in the family Flaviviridae. HCV has a high rate of replication with approximately one trillion particles produced each day in an infected individual. Due to lack of proofreading by the HCV RNA polymerase, the HCV has an exceptionally high mutation rate, a factor that may help it elude the host's immune response. Hepatitis C virus is classified into six genotypes(1-6) with several subtypes within each genotype. The preponderance and distribution of HCV genotypes varies globally. Genotype is clinically important in determining potential response to interferon-based therapy and the required duration of such therapy. Genotypes 1 and 4 are less responsive to interferon-based treatment than are the other genotypes (2, 3, 5 and 6).